China approves first commercial brain-computer interface
China's National Medical Products Administration approved NEO, an invasive brain-computer interface developed by Shanghai-based Neuracle Technology and Tsinghua University researchers, marking the first such device cleared for commercial use beyond clinical trials. The coin-sized implant, placed on the brain's protective membrane rather than penetrating brain tissue, has enabled paralyzed patients to regain limited motor control. Dong Hui, a 39-year-old paralyzed from a spinal cord injury, regained enough hand function to write after 11 months of training with the device.
TL;DR
- NEO became the world's first invasive BCI approved for commercial use beyond clinical trials in March 2026
- The device sits on the dura mater rather than penetrating brain tissue, presenting lower surgical risk than competitors like Neuralink's N1
- Neuracle conducted 36 clinical trials since October 2023, with 32 occurring in 2025, enabling rapid regulatory approval
- NEO is approved for patients aged 18 to 60 with spinal cord injuries causing limb paralysis but retaining some arm function
Why It Matters
This approval represents a significant milestone in brain-computer interface commercialization and demonstrates China's regulatory willingness to fast-track medical devices in this space. The device's less invasive design, which avoids direct cortex penetration, may offer a safer pathway for BCI adoption compared to alternatives. The approval signals that invasive BCIs are moving from experimental research into clinical practice for specific patient populations.
Business Impact
NEO's approval establishes a commercial market for invasive BCIs and validates Neuracle's technology platform ahead of competitors. The device's regulatory clearance in China creates a first-mover advantage and may influence global regulatory standards for BCI approval. Companies developing BCIs now face a competitive timeline as China demonstrates faster approval pathways than Western regulators.
Key Implications
- Invasive BCIs are transitioning from clinical research to commercial medical products, creating a new market segment for neurotechnology companies
- China's regulatory approach to BCIs may differ from Western standards, potentially accelerating device approval in China while creating divergent global standards
- The less invasive design of NEO compared to penetrating electrodes may become a competitive advantage in regulatory approval and patient safety perception
- Rapid clinical trial expansion in 2025 suggests Chinese companies can compress development timelines significantly compared to Western precedents
What to Watch
Monitor whether other BCI developers, including Neuralink, achieve similar regulatory approvals and on what timeline. Track clinical outcomes for NEO patients over the next 12 to 24 months to assess long-term safety and efficacy. Watch for expansion of NEO's approved patient population beyond spinal cord injury and whether other Chinese regulatory bodies adopt similar approval frameworks for neurotechnology.
Subscribe to the newsletter
The latest stories and analysis, delivered to your inbox.
Free. No spam. Unsubscribe any time.
